VTX-0P4 / Voltron Therap - LARVOL DELTA

VTX-P04, a Self-Assembling Immunotherapy Targeting PSCA, Induces T Cell Responses and Inhibits TRAMP-C2 Tumor Growth in a C57BL/6 Mouse Model of Prostate Cancer (SITC 2025) - "When combined with anti-PD-1 therapy, VTX-P04 enhances survival and reduces tumor burden in a preclinical prostate cancer model. These results, along with our prior work on a Lassa fever vaccine,1 support the potential of our SACI platform for application across infectious disease and oncology settings."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Skin Cancer • Solid Tumor • CD4 • CD8 • IFNG • PSCA

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen (PRNewswire) - "Voltron Therapeutics, Inc...today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA). PSCA is a key target in the treatment of Prostate Cancer....'In our HPV-related cancer proof of concept trial, Voltron validated that targeting hot spot epitopes, E6/E7, can lead to highly statistically significant increases in survival, reduced tumor growth, and increased tumor infiltration by beneficial immune T Cells...As with our HPV design, this trial will also evaluate the specific vaccine as monotherapy and in combination with a Checkpoint Inhibitor (PD-1).'"

Clinical protocol • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Lucius Partners Portfolio Company Voltron Therapeutics Announces Robust Immunogenicity Data: Key Prostate Cancer Target (EIN News) - "Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that the Dose-Ranging Immunogenicity Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA), induced robust, statistically significant immune responses in a dose dependent manner compared to controls. This is an important target in the fight against Prostate Cancer. The study utilized a well-established mouse model of PSCA expressing cancers including prostate, bladder, and kidney cancers. Importantly, this trial validated the ability of Voltron’s targeted vaccines to train T cells to mount specific responses to immunogenic proteins, in addition to its previously shown ability to generate immune responses to peptides, and further confirmed that the SAV is well tolerated."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial (PRNewswire) - "Voltron Therapeutics, Inc...announced today that it has signed a new Sponsored Research Agreement (SRA) with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline....The Self-Assembling Vaccine (SAV) targeting HPV demonstrated a positive and highly statistically significant survival improvement in a dose-related manner. This new pre-clinical program will leverage that important work and expand the Company's potential pipeline into additional types of antigens and cancers."

Licensing / partnership • Genito-urinary Cancer • Kidney Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer